NEUP
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

Neuphoria Therapeutics Inc. is a clinical-stage biotechnology company focused on developing treatments for neuropsychiatric disorders. Its lead product candidate, BNC210, is an oral, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor, previously evaluated in clinical trials for social anxiety disorder and post-traumatic stress disorder. Following the discontinuation of its social anxiety disorder program, the company maintains clinical readiness for BNC210 in post-traumatic stress disorder while managing intellectual property and economic interests in partnered programs. These partnerships include Merck’s alpha7 receptor positive allosteric modulator portfolio, the KAT6 program licensed to Pfizer, and Carina Biotech’s CNA3103 program. Neuphoria has entered into a definitive merger agreement with Scancell Holdings plc, under which it will become an indirect wholly owned subsidiary of Scancell.

Summarised from the company's own disclosures, fiscal year ended Sep 2026

Industry Biotechnology Homepage neuphoriatx.com
Sector Healthcare IR page ir.neuphoriatx.com
Tags
neuropsychiatric disorders, alpha7 nicotinic acetylcholine receptor, negative allosteric modulators, social anxiety disorder, post-traumatic stress disorder, small molecule therapeutics, clinical-stage development, BNC210, MK-4334, MK-1167, CNA3103, Scancell Holdings plc, Merck, Pfizer, Carina Biotech, Cancer Therapeutics Cooperative Research Centre
Press page —

Metrics

Valuation  
Market cap $ 19.264M
Market cap (USD) $ 19.264M
P/E -1.72
PEG —
P/BV 0.82
P/S 16.41
P/OCF -1.56
P/FCF -1.31
Dividend yield —
Turnover / mcap —
Returns  
ROE -61.7%
ROI -54.7%
ROIC -50.2%
Profit margin -1,145.7%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 10
Quality score -76.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Revenue 1.174M 15.649M — 15.067K 190.893K 0
Net profit -13.452M -369.632K -15.492M -21.764M 661.359K 0
Free cash flow — — -14.681M -10.003M -15.754M —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 4.37 7.1 — — — —
Price performance 12m -0.38 — — — — —

Filed figures

Figure Jun 2020 Jun 2021 Jun 2022 Jun 2023 Jun 2024 Jun 2025 Jun 2026
Balance sheet detail
Trade receivables (USD) — — — 426,087 126,884 11,948 813,431
↳ YoY growth -70.2% -90.6% +6,708.1%
Lease liabilities (USD) — — — 353,765 239,618 116,314 —
Cash and deposits (USD) — — 23.2M 12.1M 12.6M 14.2M 19.9M
Intangible assets (USD) — — 0.00 6.13M 5.47M 4.8M 4.14M
Right-of-use assets (USD) — — — 330,478 216,975 102,612 —
Cash flow detail
Operating cash flow (USD) — — — -14.6M -14.7M 77,229 -12.4M
Change in receivables (cash effect) (USD) — — — 4.14M 299,203 114,936 -801,483
Change in payables (cash effect) (USD) — — — 374,176 804,371 -917,663 -768,785
Interest paid (cash effect) (USD) — — — — -31,516 -17,433 -3,857
Income taxes paid (cash effect) (USD) — — — — -51,853 — —
Share-based compensation (USD) — — — 1.35M 814,808 163,772 351,600
Operating cash flow before change in receivables (USD) — — — -18.8M -15M -37,707 -11.6M
Income detail
Research and development expense (AUD) 5.83M 5.76M 16M 19.6M 9.42M 9.01M —
Total comprehensive income (USD) — — — -22.4M -15.4M -201,103 -12.7M
Comprehensive income to owners (USD) — — — -22.4M -15.4M -201,103 -12.7M
Reported Oct 14, 2022 Oct 14, 2022 Sep 30, 2024 Sep 30, 2024 Sep 30, 2024 Sep 29, 2025 Sep 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

On October 23, 2026, the Board of Directors (the “Board”) of Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”), a Delaware corporation, entered into Amendment No. 1 (the “Amendment”) to the Rights Agreement, dated as of October 27, 2025, by and between the Company and Computershare Trust Company, N.A., as Rights Agent (the “Original Rights Agreement,” and as amended by the Amendment). Pursuant to the Amendment, the Final Expiration Date of the Original Rights Agreement has been extended until the Close of Business on October 27, 2027, unless earlier extended, modified or terminated. Capitalized terms used but not defined herein have the meanings specified in the Rights Agreement, as amended.

The Rights are in all respects subject to and governed by the provisions of the Original Rights Agreement, except as as amended by the Amendment. The above description of the Original Rights Agreement and the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Original Rights Agreement, which is incorporated by reference to Exhibit 4.1 to the Form 8-K filed by the Company with the U.S.

● All-share transaction creating a combined company to operate as Scancell advancing a pipeline of targeted, off-the-shelf, active immunotherapies

● Combined company to be listed on Nasdaq, in addition to Scancell’s existing AIM listing

● Agreed pro forma merger ownership split: existing Scancell shareholders to own 85.5 per cent. of the combined company, with Neuphoria existing shareholders owning 14.5 per cent.1

● Financing to fund the global registrational Phase 3 trial for lead programme, iSCIB1+ active immunotherapy in advanced melanoma

OXFORD, UK and BURLINGTON, MASS., 23 July 2026 – Scancell Holdings plc (AIM: SCLP) (“Scancell”) and Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria”) today announce an all-share merger in which Scancell will acquire Neuphoria. Upon completion of the Transaction, the combined company plans to operate under the name Scancell and will apply to trade on Nasdaq under the symbol “SCLT”.

Alongside the Merger, Scancell expects to secure up to $89 million of financing through a combination of equity and debt.

Jun 26, 2026

PDF Version

Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination

BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (“Neuphoria” or the “Company”) (NASDAQ: NEUP), a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders, today issued the following statement in response to an announcement made by London-listed biotechnology company Scancell Holdings plc (“Scancell”).

The Neuphoria Board notes the announcement made by Scancell earlier today about a possible combination with Neuphoria. The Scancell announcement was made following speculation in the UK press and in compliance with UK regulations.

The Board can confirm that it is in discussions with Scancell about the potential acquisition of Neuphoria by Scancell, with Scancell becoming a Nasdaq-listed company following closing of any such transaction.

There can be no certainty that any agreement will be reached with Scancell, the terms of any transaction or if any transaction will proceed at all.

Any further announcements will be made in compliance with applicable SEC and Nasdaq regulations.

About Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc. (Nasdaq: NEUP) is a public company incorporated in Delaware. The Company is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. Neuphoria is advancing the lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor for the treatment of post-traumatic stress disorder (“PTSD”). BNC210 is a first-of-its-kind, well tolerated, broad spectrum anti-anxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. Following the announcement from the AFFIRM-1 Phase 3 clinical trial on October 20, 2025, in which the Company announced that the trial missed its primary and secondary endpoints, the Company has halted development of BNC210 in social anxiety disorder and is conducting a strategic review. In addition, Neuphoria has a strategic partnership with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions. Neuphoria’s pipeline also includes the α7 nicotinic acetylcholine receptor next generation and the Kv3.1/3.2 preclinical programs, both in the lead optimization development stage.

Forward-Looking Statements

Neuphoria cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs, plans, burn rate and expectations. Certain forward-looking statements, including (without limitation) about (1) Neuphoria’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement and/or completion, as well as any successful or other outcome of various clinical trials, and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat central nervous system diseases and pain conditions, and the Company’s ability to realize the commercial potential of its products, as well as its regulatory strategy related to its clinical trials and, if successful, the regulatory pathway to any next stage in development or commercialization, (3) Neuphoria’s financial resources, and capital allocation and corporate development strategy, (4) the Board’s review of strategic alternatives and evaluation of offers from third parties, and (5) assumptions underlying any such statements. The inclusion of forward-looking statements should not be regarded as a representation by Neuphoria that any of its plans will be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. Certain forward-looking statements involve contracts, licenses and arrangements involving third parties and their respective clinical trial and research and development projects that are out of our control, including our agreements with our strategic partners. They may terminate or delay any or all such projects in their discretion pursuant to the terms of our agreements with them, which could result in the Company not realizing any further milestone payments or further progress on the respective product pathways. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business and other risks described in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Reports on Form 8-K, each filed with the SEC, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Neuphoria undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks, uncertainties and other factors is included in Neuphoria’s filings with the SEC, copies of which are available from the SEC’s website (www.sec.gov) and on Neuphoria’s website (www.neuphoriatx.com) under the heading “Investor Center.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Neuphoria expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Prompts

Neuphoria Therapeutics Inc. (ticker NEUP), listed in United States.

Company History

Date Change Detail
Nov 21, 2024 Renamed BIONOMICS LIMITED/FI → NEUPHORIA THERAPEUTICS INC.
Jun 30, 2024 Reporting currency Its US reports are in USD instead of AUD from this period. Earlier figures are shown in USD, converted at each period end's exchange rate.
— Former tickers BNOX

ETFs Holding Neuphoria Therapeutics Inc.

ETF Weight in ETF Shares Market value As of
PSIL 1.73% 290,653 $ 659.782K Nov 17, 2026